Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 17 04:00PM ET
4.78
Dollar change
-0.36
Percentage change
-7.00
%
IndexRUT P/E- EPS (ttm)-8.68 Insider Own3.85% Shs Outstand26.56M Perf Week-10.99%
Market Cap131.05M Forward P/E4.76 EPS next Y1.00 Insider Trans0.00% Shs Float26.36M Perf Month37.36%
Income-190.81M PEG- EPS next Q1.03 Inst Own32.02% Short Float14.66% Perf Quarter176.30%
Sales99.52M P/S1.32 EPS this Y74.98% Inst Trans12.24% Short Ratio3.90 Perf Half Y55.19%
Book/sh-12.87 P/B- EPS next Y137.92% ROA-83.45% Short Interest3.87M Perf Year-70.12%
Cash/sh0.67 P/C7.09 EPS next 5Y38.34% ROE- 52W Range1.38 - 18.74 Perf YTD74.45%
Dividend Est.- P/FCF- EPS past 5Y7.90% ROIC- 52W High-74.49% Beta1.43
Dividend TTM- Quick Ratio0.11 Sales past 5Y-7.17% Gross Margin86.25% 52W Low246.38% ATR (14)0.49
Dividend Ex-Date- Current Ratio0.11 EPS Y/Y TTM31.19% Oper. Margin-105.36% RSI (14)55.61 Volatility7.55% 9.73%
Employees316 Debt/Eq- Sales Y/Y TTM-38.34% Profit Margin-191.72% Recom2.20 Target Price11.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q65.97% Payout- Rel Volume0.65 Prev Close5.14
Sales Surprise9.48% EPS Surprise37.73% Sales Q/Q-14.07% EarningsMay 12 BMO Avg Volume991.14K Price4.78
SMA206.58% SMA5040.55% SMA20035.40% Trades Volume645,673 Change-7.00%
Date Action Analyst Rating Change Price Target Change
Jun-04-25Upgrade H.C. Wainwright Neutral → Buy $25
Jul-19-24Downgrade Robert W. Baird Outperform → Neutral $35 → $8
Jul-18-24Downgrade William Blair Outperform → Mkt Perform
Jul-18-24Downgrade H.C. Wainwright Buy → Neutral $9
Jun-06-23Initiated Robert W. Baird Outperform $8
Jun-06-23Initiated Robert W. Baird Outperform $60 → $80
Feb-28-23Resumed H.C. Wainwright Buy $8
Sep-28-22Initiated SMBC Nikko Outperform $5
Dec-16-21Initiated H.C. Wainwright Buy $12
Nov-19-19Resumed B. Riley FBR Buy $6
Jun-17-25 12:02PM
10:30AM
07:30AM
Jun-16-25 03:01PM
08:45AM
01:30PM Loading…
Jun-10-25 01:30PM
Jun-05-25 10:03AM
Jun-04-25 09:55AM
07:33AM
Jun-03-25 07:00AM
May-30-25 07:30AM
May-29-25 11:18AM
11:08AM
May-19-25 09:06AM
08:50AM
10:45AM Loading…
May-16-25 10:45AM
May-15-25 10:40AM
08:42AM
May-14-25 06:29AM
May-13-25 03:03AM
02:57AM
May-12-25 08:50AM
07:47AM
07:30AM
07:20AM
May-09-25 09:47AM
09:40AM
May-08-25 09:25AM
May-07-25 06:15PM
12:42PM
05:15PM Loading…
May-05-25 05:15PM
Apr-29-25 10:01AM
07:30AM
Apr-28-25 03:30PM
Apr-25-25 01:05PM
Apr-23-25 12:05PM
09:40AM
Apr-10-25 08:52AM
Mar-25-25 04:40PM
09:55AM
Mar-19-25 07:30AM
Mar-12-25 03:03AM
01:35AM
Mar-11-25 11:45AM
08:40AM
07:43AM
07:30AM
Feb-26-25 04:48PM
Feb-25-25 02:30PM
08:26AM
Feb-24-25 08:33AM
Feb-23-25 07:38PM
Feb-21-25 09:40AM
Feb-06-25 08:50AM
Feb-05-25 09:40AM
Jan-29-25 12:37PM
Jan-22-25 02:48PM
Jan-20-25 12:00PM
09:40AM
Dec-18-24 07:30AM
Dec-06-24 06:07AM
Dec-05-24 07:30AM
Nov-27-24 10:20AM
08:15AM
Nov-19-24 09:35AM
Nov-18-24 09:35AM
Nov-15-24 09:35AM
Nov-13-24 02:18AM
02:08AM
Nov-12-24 12:15PM
08:20AM
07:19AM
07:00AM
Nov-11-24 07:24AM
Nov-07-24 10:00AM
07:00AM
Nov-05-24 07:30AM
Nov-01-24 05:45AM
Oct-29-24 05:45AM
Sep-19-24 01:31PM
Sep-17-24 05:45AM
Sep-16-24 12:51PM
Sep-13-24 10:00AM
Sep-09-24 07:30AM
Sep-03-24 07:30AM
Aug-08-24 04:15PM
08:10AM
07:08AM
07:00AM
07:00AM
Aug-07-24 10:58AM
Aug-05-24 02:31PM
07:23AM
Aug-01-24 10:01AM
Jul-26-24 07:00AM
Jul-19-24 10:39AM
07:47AM
Jul-18-24 07:00AM
Jun-28-24 11:10AM
Jun-27-24 07:30AM
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.